3,624 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 3,624 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000.

Several other large investors have also bought and sold shares of MDGL. Kohmann Bosshard Financial Services LLC acquired a new stake in Madrigal Pharmaceuticals in the fourth quarter worth $70,000. KBC Group NV grew its stake in Madrigal Pharmaceuticals by 73.5% in the 4th quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 258 shares during the period. Miracle Mile Advisors LLC purchased a new position in Madrigal Pharmaceuticals in the fourth quarter valued at about $216,000. D.A. Davidson & CO. purchased a new position in Madrigal Pharmaceuticals in the fourth quarter valued at approximately $221,000. Finally, Atria Investments Inc purchased a new stake in Madrigal Pharmaceuticals in the fourth quarter worth $222,000. 98.50% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ MDGL opened at $314.39 on Friday. The stock’s 50-day moving average is $333.68 and its 200 day moving average is $300.30. The stock has a market cap of $6.94 billion, a price-to-earnings ratio of -12.54 and a beta of -0.68. Madrigal Pharmaceuticals, Inc. has a 1-year low of $189.00 and a 1-year high of $377.46. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.32) by $1.61. The business had revenue of $103.32 million during the quarter, compared to the consensus estimate of $97.81 million. On average, sell-side analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.

Analysts Set New Price Targets

MDGL has been the subject of a number of recent analyst reports. Citigroup lifted their target price on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a report on Thursday, February 27th. HC Wainwright upped their target price on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. Finally, B. Riley raised shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and upped their price target for the stock from $236.00 to $422.00 in a report on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $378.44.

Insider Activity

In other Madrigal Pharmaceuticals news, VP Robert E. Waltermire sold 103 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $335.24, for a total transaction of $34,529.72. Following the completion of the sale, the vice president now directly owns 4,955 shares in the company, valued at $1,661,114.20. The trade was a 2.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Rebecca Taub sold 1,689 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $273.41, for a total transaction of $461,789.49. Following the completion of the transaction, the chief marketing officer now directly owns 457,310 shares in the company, valued at approximately $125,033,127.10. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,900 shares of company stock worth $12,168,079 over the last three months. 22.80% of the stock is currently owned by corporate insiders.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.